The extreme genetic diversity of the human immunodeficiency virus type 1 (HIV-1) poses a daunting challenge to the generation of an effective AIDS vaccine. In Argentina, the epidemic is characterized by the high prevalence of infections caused by subtype B and BF variants. The aim of this study was to characterize in mice the immunogenic and antigenic properties of the Env protein from CRF12_BF in comparison with clade B, employing prime-boost schemes with the combination of recombinant DNA and vaccinia virus (VV) vectors.Significantly, application of a mixed immunization combining both clades (B and BF) induced a broader cellular response, in which the majority of the peptides targeted after the single clade vaccinations generated a positi...
Recombinants based on the attenuated vaccinia virus strains MVA and NYVAC are considered candidate v...
Recent studies have reported that founder viruses play unique roles in establishing HIV-1 infection....
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
The extreme genetic diversity of the human immunodeficiency virus type 1 (HIV-1) poses a daunting ch...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
<div><p>In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF re...
Consensus HIV-1 genes can decrease the genetic distances between candidate immunogens and field viru...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
Consensus HIV-1 genes can decrease the genetic distances between candidate immunogens and field viru...
<div><p>In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env pro...
In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein wit...
Recombinants based on the attenuated vaccinia virus strains MVA and NYVAC are considered candidate v...
Recent studies have reported that founder viruses play unique roles in establishing HIV-1 infection....
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
The extreme genetic diversity of the human immunodeficiency virus type 1 (HIV-1) poses a daunting ch...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
<div><p>In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF re...
Consensus HIV-1 genes can decrease the genetic distances between candidate immunogens and field viru...
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinan...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
Consensus HIV-1 genes can decrease the genetic distances between candidate immunogens and field viru...
<div><p>In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env pro...
In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein wit...
Recombinants based on the attenuated vaccinia virus strains MVA and NYVAC are considered candidate v...
Recent studies have reported that founder viruses play unique roles in establishing HIV-1 infection....
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...